Table 4.

Assessment of TA-GVHD

Group4-150Spleen Index (spleen wt/body wt ×1,000) % Donor T-cell Engraftment Thymic Cellularity (×107 cells)
Control  3.67 ± 0.2 (n = 6) 0.25 ± 0.05 (n = 2)  5.5 ± 0.9 (n = 6)  
GVHD4-151 18.75 ± 1.3 (n = 4)  34.34 ± 2.2 (n = 2) 1.2 ± 0.2 (n = 4)  
Gamma  3.64 ± 0.4 (n = 4) 0.53 ± 0.05 (n = 2)  3.8 ± 0.6 (n = 4)  
PCT 3.66 ± 0.3 (n = 4)  0.41 ± 0.03 (n = 2) 3.8 ± 0.6 (n = 4) 
Group4-150Spleen Index (spleen wt/body wt ×1,000) % Donor T-cell Engraftment Thymic Cellularity (×107 cells)
Control  3.67 ± 0.2 (n = 6) 0.25 ± 0.05 (n = 2)  5.5 ± 0.9 (n = 6)  
GVHD4-151 18.75 ± 1.3 (n = 4)  34.34 ± 2.2 (n = 2) 1.2 ± 0.2 (n = 4)  
Gamma  3.64 ± 0.4 (n = 4) 0.53 ± 0.05 (n = 2)  3.8 ± 0.6 (n = 4)  
PCT 3.66 ± 0.3 (n = 4)  0.41 ± 0.03 (n = 2) 3.8 ± 0.6 (n = 4) 
F4-150

Control, syngeneic control; GVHD, allogeneic control; Gamma, allogeneic, gamma radiation (2,500 cGy); PCT, allogeneic, S-59 (150 μmol/L) and UVA (2.1 J/cm2).

F4-151

For all of the parameters the GVHD group was statistically different from the PCT, Gamma, and Control group when analyzed by Student’st-test (P > .05). Differences among the Control, PCT, and Gamma groups were not significant when analyzed by Student’st-test (P > .05). The mean values, standard error, and the number of mice used (n) is indicated for each treatment group and assay.